Infectious disease research and biotechnology by Vir Biotechnology
Vir Biotechnology advances dual-masked TCE pipeline targeting difficult-to-treat solid tumors
Vir Biotechnology announced progress in advancing its clinical and pre-clinical pipeline of dual-masked T-cell engagers (TCEs) aimed at treating multiple challenging solid tumors. The company ...
Vir Biotechnology to hold investor call on Q3 2026 performance
Vir Biotechnology has announced it will release its financial results for the third quarter of 2026 on Wednesday, November 4, immediately following the close of U.S. markets. The company has ...
Vir Biotechnology advances Phase 3 ECLIPSE program for Hepatitis Delta treatment
Vir Biotechnology announced ongoing progress in its Phase 3 ECLIPSE clinical program, pursuing a potential best-in-class treatment for Hepatitis Delta. The company expressed encouragement about ...
Gilead Sciences partners with Vir Biotechnology to advance multi-program solid tumor therapies
Vir Biotechnology has announced a multi-program collaboration and license agreement with Gilead Sciences focusing on the discovery and engineering of novel PRO-XTEN dual-masked T-cell engagers ...
Vir Biotechnology appoints David Liu as executive vice president and chief medical officer
Vir Biotechnology has named David Liu as executive vice president and chief medical officer. The company stated that Liu brings significant experience in immuno-oncology and global regulatory ...
Vir Biotechnology unveils new clinical data on oral therapies for chronic Hepatitis Delta
Vir Biotechnology announced it will present expanded Phase 2 SOLSTICE clinical trial results evaluating its investigational drugs elebsiran and tobevibart for chronic Hepatitis Delta. The ...
Vir Biotechnology appoints Aziz Sawaf as EVP and CFO
Vir Biotechnology has announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer. Sawaf will oversee the company’s finance, operations, information ...
Vir Biotechnology celebrates 10 years advancing science and embracing transformation
Vir Biotechnology is commemorating its tenth anniversary, reflecting on a decade marked by growth, innovation and transformation. The company credits its commitment to scientific rigor as a ...
Vir Biotechnology CEO Marianne De Backer to address Morgan Stanley Global Healthcare Conference
Vir Biotechnology announced that its President and CEO, Marianne De Backer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at ...
Vir Biotechnology unveils decade-long timeline spotlighting research advances and company culture
Vir Biotechnology is commemorating its 10-year anniversary by publishing a timeline that highlights key moments from the past decade. The retrospective covers major scientific progress, ...
Vir Biotechnology welcomes families and friends to company labs during 10 year anniversary event
Vir Biotechnology brought together employees’ families, friends, and loved ones for a special Family Day as part of its 10 year anniversary activities. Attendees toured the company’s ...
Vir Biotechnology boosts financial position as CHD and oncology portfolios advance
Vir Biotechnology disclosed its second quarter 2026 financial results, revealing a robust cash position exceeding 1.0 billion dollars. The company reported ongoing progress in its chronic ...
Vir Biotechnology to report Q2 2026 results on August 5 as investors await financial update
Vir Biotechnology is set to deliver a corporate update and announce its second-quarter 2026 financial results on Wednesday, August 5, at 4:30 p.m. ET. The company will host an investor ...
Biotech executives convene under Vir Biotechnology leadership to drive innovation at BIO2026
Marianne De Backer, CEO of Vir Biotechnology, joined fellow members of the IAmBiotech Board of Directors to kick off BIO2026. The event brings together leading figures from the biotech ecosystem ...
Vir Biotechnology unveils early Phase 1 data for VIR-5500 in metastatic prostate cancer at ASCO2026
Vir Biotechnology announced it has presented early Phase 1 clinical data for its candidate VIR-5500 targeting metastatic prostate cancer at ASCO2026. The company also highlighted its strategic ...
Week 96 SOLSTICE trial results advance Vir Biotechnology pursuit of chronic hepatitis D treatment
Vir Biotechnology has announced new data from its Phase 2 SOLSTICE trial demonstrating sustained suppression of hepatitis D virus (HDV) at Week 96. The results, shared during the final day of ...
Vir Biotechnology to present BMI impact on ALT normalization at EASL2026 Phase 2 SOLSTICE analysis
Vir Biotechnology is set to present new findings from its Phase 2 SOLSTICE Week 48 subgroup analysis, focusing on the impact of body mass index (BMI) on ALT normalization in participants with ...
Vir Biotechnology strategy shifts to clinic-ready pipeline focus
Vir Biotechnology is directing its efforts toward creating a next-generation pipeline, according to CEO Marianne de Backer. The shift centers on ensuring that programs entering the clinic will ...
Vir Biotechnology schedules Q1 2026 earnings call for 4:30 p.m. ET
Vir Biotechnology has announced it will deliver a corporate update and release its first-quarter 2026 financial results during an investor conference call at 4:30 p.m. ET and 1:30 p.m. PT. The ...
Vir Biotechnology schedules CEO fireside chat at major healthcare event
Vir Biotechnology will participate in the Bank of America Securities 2026 Healthcare Conference with a fireside chat featuring Chief Executive Officer Marianne De Backer, MSc, PhD, MBA, on May 12 ...
